The pretreatment neutrophil/lymphocyte ratio is associated with all-cause mortality in black and white patients with non-metastatic breast cancer

Frontiers in Oncology

Volumn 6, Issue MAR, 2016, Pages

  Rimando, Joseph ^a   Campbell, Jeff ^a   Kim, Jae Hee ^a   Tang, Shou Ching ^a   Kim, Sangmi ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

All cause mortality; Black patients; Breast cancer; Neutrophil lymphocyte ratio; White patients

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BODY MASS; BREAST CANCER; CANCER STAGING; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NEUTROPHIL LYMPHOCYTE RATIO; RACE; RETROSPECTIVE STUDY; SMOKING;

EID: 84964553537     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00081     Document Type: Article

References (55)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin (2015) 65(1):5-29. doi: 10.3322/caac.21254
2. American Joint Committee on Cancer. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. New York: Springer (2002)
3. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 41(3a):403-10. doi:10.1111/j.1365-2559.1991.tb00229.x
4. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer (1980) 46(S12):2884-8. doi:10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235(21):0-5. doi:10.1126/science.3798106
6. Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, Foulkes WD. Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology (2011) 58(7):1107-16. doi:10.1111/j.1365-2559.2011.03846.x
7. Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol (2014) 25(8):1536-43. doi:10.1093/annonc/mdu191
8. Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res (2011) 13(3):R55. doi:10.1186/bcr2891
9. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets (2010) 11(9):1133-46. doi:10.2174/138945010792006799
10. Wang S, Zhang Z, Fang F, Gao X, Sun W, Liu H. The neutrophil/lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis. Oncol Lett (2011) 2:735-40. doi:10.3892/ol.2011.304
11. Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short-and long-term mortality in breast cancer patients. Ann Surg Oncol (2012) 19(1):217-24. doi:10.1245/s10434-011-1814-0
12. Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol (2013) 30(1):432. doi:10.1007/s12032-012-0432-4
13. Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer (2013) 16(1):55-9. doi:10.4048/jbc.2013.16.1.55
14. Nakano K, Hosoda M, Yamamoto M, Yamashita H. Prognostic significance of pre-treatment neutrophil: lymphocyte ratio in Japanese patients with breast cancer. Anticancer Res (2014) 34:3819-24
15. Forget P, Machiels J-P, Coulie PG, Berliere M, Poncelet AJ, Tombal B, et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol (2013) 20(Suppl 3):S650-60. doi:10.1245/s10434-013-3136-x
16. Eryilmaz MK, Mutlu H, Salim DK, Yalcin F, Tural D, Coskun HS. The neutrophil to lymphocyte ratio has a high negative predictive value for pathologic complete response in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. Asian Pac J Cancer Prev (2014) 15:7737-40. doi:10.7314/APJCP.2014.15.18.7737
17. Chen J, Deng Q, Pan Y, He B, Ying H, Sun H, et al. Prognostic value of neutrophil-to-lymphocyte ratio in breast cancer. FEBS Open Bio (2015) 5:502-7. doi:10.1016/j.fob.2015.05.003
18. Koh C-H, Bhoo-Pathy N, Ng K-L, Jabir RS, Tan G-H, See M-H, et al. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer (2015) 113(1):150-8. doi:10.1038/bjc.2015.183
19. Pistelli M, De Lisa M, Ballatore Z, Caramanti M, Pagliacci A, Battelli N, et al. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer (2015) 15(1):195. doi:10.1186/s12885-015-1204-2
20. Kaneko M, Nozawa H, Sasaki K, Hongo K, Hiyoshi M, Tada N, et al. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in advanced colorectal cancer patients receiving oxaliplatin-based chemotherapy. Oncology (2012) 82(5):261-8. doi:10.1159/000337228
21. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg (2009) 137(2):425-8. doi:10.1016/j.jtcvs.2008.05.046
22. Cedrés S, Torrejon D, Martínez A, Martinez P, Navarro A, Zamora E, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol (2012) 14(11):864-9. doi:10.1007/s12094-012-0872-5
23. Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol (2010) 184(3):873-8. doi:10.1016/j.juro.2010.05.028
24. Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer (2012) 48(2):202-8. doi:10.1016/j.ejca.2011.09.001
25. Shimada H, Takiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, et al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer (2010) 13(3):170-6. doi:10.1007/s10120-010-0554-3
26. Jung MR, Park YK, Jeong O, Seon JW, Ryu SY, Kim DY, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol (2011) 104(5):504-10. doi:10.1002/jso.21986
27. An X, Ding PR, Wang FH, Jiang WQ, Li YH. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma. Tumour Biol (2011) 32(2):317-24. doi:10.1007/s13277-010-0124-7
28. He J, Shen G, Ren A, Qin H, Cui C, Zhang Y, et al. Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma. Head Neck (2012) 34(12):1769-76. doi:10.1002/hed.22008
29. Gomez D, Farid S, Malik HZ, Young L, Toogood GJ, Lodge JP, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg (2008) 32(8):1757-62. doi:10.1007/s00268-008-9552-6
30. Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI, et al. Elevated preoperative neutrophil: lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol (2011) 18(12):3362-9. doi:10.1245/s10434-011-1754-8
31. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer (2011) 104(8):1288-95. doi:10.1038/bjc.2011.100
32. Hsieh M, Everhart J, Byrd-Holt D, Tisdale J, Rodgers G. Prevalence of neutrophenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med (2007) 146(7):486-92. doi:10.7326/0003-4819-146-7-200704030-00004
33. Mandrekar JN, Mandrekar SJ, Cha SS. Cutpoint determination methods in survival analysis using SAS. Proceedings of the 28th SAS Users Group International Conference (SUGI). Seattle (2003)
34. Heiss MM, Ströhlein MA, Bokemeyer C, Arnold D, Parsons SL, Seimetz D, et al. The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study. Clin Cancer Res (2014) 20(12):3348-57. doi:10.1158/1078-0432.CCR-13-2351
35. Coussens LM, Werb Z. Inflammation and cancer. Nature (2002) 420(6917):860-7. doi:10.1038/nature01322
36. Joyce J, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer (2009) 9(4):239-52. doi:10.1038/nrc2618
37. Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp K, et al. The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients. Tumour Biol (2015):1-8. doi:10.1007/s13277-015-3805-4
38. Grenader T, Plotkin Y, Geffen DB. The preoperative neutrophil/lymphocyte ratio does not correlate with the 21-gene recurrence score in estrogen receptor-positive breast cancer patients. Oncol Res Treat (2015) 38(1-2):24-7. doi:10.1159/000370341
39. Hong J, Mao Y, Chen X, Zhu L, He J, Chen W, et al. Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer. Tumour Biol (2015)
40. Ulas A, Avci N, Kos T, Cubukcu E, Olmez OF, Degirmenci M. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab? J BUON (2015) 20(3):714-22
41. Bonecchi R, Borroni EM, Savino B, Buracchi C, Mantovani A, Locati M. Non-signaling chemokine receptors: mechanism of action and role in vivo. J Neuroimmunol (2008) 198(1-2):14-9. doi:10.1016/j.jneuroim.2008.04.018
42. Reich D, Nalls MA, Kao WHL, Akylbekova EL, Tandon A, Patterson N, et al. Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genet (2009) 5(1):e1000360. doi:10.1371/journal.pgen.1000360
43. Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. Mol Cell Endocrinol (2014) 382(1):673-82. doi:10.1016/j.mce.2013.06.003
44. Characiejus D, Jacobs JJL, Pašukoniene V, Kazlauskaite N, Danileviciute V, Mauricas M, et al. Prediction of response in cancer immunotherapy. Anticancer Res (2011) 31(2):639-47
45. Dirican N, Karakaya Y, Gunes S, Daloglu F, Dirican A. Association of intratumoral tumor infiltrating lymphocytes and neutrophil-to-lymphocyte ratio are an independent prognostic factor in non-small cell lung cancer. Clin Respir J (2015). doi:10.1111/crj.12417
46. Blum KS, Pabst R. Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs? Immunol Lett (2007) 108(1):45-51. doi:10.1016/j.imlet.2006.10.009
47. Ross R. Inflammation or atherogenesis. N Engl J Med (1999) 340(2):115-26
48. Proctor MJ, McMillan DC, Horgan PG, Fletcher CD, Talwar D, Morrison DS. Systemic inflammation predicts all-cause mortality: a Glasgow Inflammation Outcome Study. PLoS One (2015) 10(3):e0116206. doi:10.1371/journal.pone.0116206
49. Verdoia M, Barbieri L, Di Giovine G, Marino P, Suryapranata H, De Luca G, et al. Neutrophil to lymphocyte ratio and the extent of coronary artery disease: results from a large cohort study. Angiology (2016) 67(1):75-82. doi:10.1177/0003319715577529
50. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res (2011) 13(3):R64. doi:10.1186/bcr2901
51. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst (2004) 96(17):1311-21. doi:10.1093/jnci/djh253
52. Núñez J, Núñez E, Bodí V, Sanchis J, Miñana G, Mainar L, et al. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am J Cardiol (2008) 101(6):747-52. doi:10.1016/j.amjcard.2007.11.004
53. Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol (2008) 102(6):653-7. doi:10.1016/j.amjcard.2008.05.006
54. Azab B, Zaher M, Weiserbs KF, Torbey E, Lacossiere K, Gaddam S, et al. Usefulness of neutrophil to lymphocyte ratio in predicting short-and long-term mortality after non-ST-elevation myocardial infarction. Am J Cardiol (2010) 106(4):470-6. doi:10.1016/j.amjcard.2010.03.062
55. Uthamalingam S, Patvardhan EA, Subramanian S, Ahmed W, Martin W, Daley M, et al. Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am J Cardiol (2011) 107(3):433-8. doi:10.1016/j.amjcard.2010.09.039